Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2-Reference-Cited by-同舟云学术

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

Published:2011-12-02 Issue:1 Volume:158A Page:24-41
ISSN:1552-4825
Container-title:American Journal of Medical Genetics Part A
language:en
Short-container-title:Am. J. Med. Genet.

Author:

Blakeley Jaishri O.,Evans D. Gareth,Adler John,Brackmann Derald,Chen Ruihong,Ferner Rosalie E.,Hanemann C. Oliver,Harris Gordon,Huson Susan M.,Jacob Abraham,Kalamarides Michel,Karajannis Matthias A.,Korf Bruce R.,Mautner Victor-Felix,McClatchey Andrea I.,Miao Harry,Plotkin Scott R.,Slattery William,Stemmer-Rachamimov Anat O.,Welling D. Bradley,Wen Patrick Y.,Widemann Brigitte,Hunter-Schaedle Kim,Giovannini Marco

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Reference115 articles.

1. Intracranial meningiomatosis causing foster kennedy syndrome by unilateral optic nerve compression and blockage of the superior sagittal sinus;Acebes;J Neuroophthalmol,2009

2. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma);American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC;Otolaryngol Head Neck Surg,1995

3. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma;Ammoun;Neuro Oncol;,2010

4. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors;Ammoun;Nat Rev Neurol;,2011

5. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2;Ammoun;Neuro Oncol;,2011

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Predisposition Syndromes in Neuro-oncology;Seminars in Neurology;2023-12-14

2. Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas;Otolaryngologic Clinics of North America;2023-06

3. Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series;Current Oncology;2023-03-20

4. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma;Neuro-Oncology;2023-02-20

5. Updates in the Management of Central and Peripheral Nervous System Tumors among Patients with Neurofibromatosis Type 1 and Neurofibromatosis Type 2;Pediatric Neurosurgery;2023